Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS8 | O00214 | 5/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | FGF1 | P05230 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | CD209 | Q9NNX6 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | OGA | O60502 | 1/20 | 0.32 |
| ▸ | MGAM | O43451 | 2/20 | 0.32 |
| ▸ | SI | P14410 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14802349 | 1.00 | LGALS8 (0.39) | LGALS8ALDH1A1HIF1AFGF1L3MBTL1 | |
| SCHEMBL15293443 | 1.00 | LGALS8 (0.39) | LGALS8ALDH1A1HIF1AFGF1L3MBTL1 | |
| SCHEMBL15267646 | 0.88 | LGALS8 (0.39) | LGALS8ALDH1A1HIF1AFGF1L3MBTL1 | |
| SCHEMBL14864284 | 0.88 | G6PD (0.33) | — | |
| SCHEMBL15267318 | 0.88 | LGALS8 (0.39) | LGALS8ALDH1A1HIF1AFGF1L3MBTL1 | |
| SCHEMBL15293425 | 0.88 | G6PD (0.33) | — | |
| SCHEMBL14802348 | 0.88 | G6PD (0.33) | — | |
| SCHEMBL23723836 | 0.88 | LGALS8 (0.43) | LGALS8ALDH1A1HIF1AFGF1L3MBTL1 | |
| SCHEMBL16504207 | 0.88 | LGALS8 (0.43) | LGALS8ALDH1A1HIF1AFGF1L3MBTL1 | |
| SCHEMBL14864297 | 0.88 | LGALS8 (0.43) | LGALS8ALDH1A1HIF1AFGF1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150284419-A1 | METHOD FOR PREPARING FULLY PROTECTION HEPARIN PENTASACCHARIDE AND INTERMEDIATE THEREOF | ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. (CN) | 2015-10-08 | — | — | US | disclosed |
| US-8288527-B2 | Oligo-aminosaccharide compound | THE UNIVERSITY OF TOKYO (JP) | 2012-10-16 | — | — | US | disclosed |
| US-20110003980-A1 | Oligo-Aminosaccharide compound | THE UNIVERSITY OF TOKYO (JP) | 2011-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003980-A1 | Oligo-Aminosaccharide compound | DDOST, STT3A, STT3B | LGALS8 625/4885ALDH1A1 4209/4885HIF1A 2701/4885 |
| US-20150284419-A1 | METHOD FOR PREPARING FULLY PROTECTION HEPARIN PENTASACCHARIDE AND INTERMEDIATE THEREOF | HABP2, HPSE, PLG | LGALS8 2747/4885ALDH1A1 2108/4885HIF1A 3276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.